Yemaachi Biotech at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Yemaachi Biotech at ASHG 2026 in Montréal: 1 presentation (1 plenary).

Organization	ASHG 2026 Attendance
Yemaachi Biotech Nairobi, Kenya	1 Country Representative, Kenya
yemaachi.com\|LinkedIn Private company Yemaachi sells clinical genomics, molecular diagnostics, and sequencing services to patients, clinicians, researchers, and life-science partners. It also develops African cancer data for precision oncology. Received a second investment from OneBio Venture Studio's Fund II, an undisclosed amount signaling continued investor confidence. › Received a second investment from OneBio Venture Studio's Fund II, an undisclosed amount signaling continued investor confidence. 2026-06 · source Its CEO Yaw Bediako also became research dean at Ashesi University, adding an academic role alongside running the company. 2025-11 · source Partnered with Bio Usawa to expand healthcare and genomics testing access across Africa, growing its regional footprint. 2025-10 · source Source: company newsroom Second OneBio Venture Studio investment (Jun 2026) › Investment amount was not disclosed. · 2026-06-02 “OneBio Venture Studio is proud to announce its second investment from Fund II into Yemaachi Biotech.” Source: funding announcement	Plenary Tue Oct 20 5:19 pm Part of Plenary Abstract Session I A whole-genome immunogenomics framework for African populations: Antigen processing, presentation, and clinically actionable diversity across the HLA, ERAP, TAP, and KIR loci Room 517/Level 5 Collaborators: Meru University of Science and Technology Immune systemComputational toolsEpidemiologyGenetic epidemiology

Organization

ASHG 2026 Attendance

Yemaachi Biotech

Nairobi, Kenya

1 Country Representative, Kenya

yemaachi.com|LinkedIn

Private company

Yemaachi sells clinical genomics, molecular diagnostics, and sequencing services to patients, clinicians, researchers, and life-science partners. It also develops African cancer data for precision oncology.

Received a second investment from OneBio Venture Studio's Fund II, an undisclosed amount signaling continued investor confidence.

›

Received a second investment from OneBio Venture Studio's Fund II, an undisclosed amount signaling continued investor confidence.

2026-06 · source

Its CEO Yaw Bediako also became research dean at Ashesi University, adding an academic role alongside running the company.

2025-11 · source

Partnered with Bio Usawa to expand healthcare and genomics testing access across Africa, growing its regional footprint.

2025-10 · source

Source: company newsroom

Second OneBio Venture Studio investment (Jun 2026)

›

Investment amount was not disclosed. · 2026-06-02

“OneBio Venture Studio is proud to announce its second investment from Fund II into Yemaachi Biotech.”

Source: funding announcement

Plenary

Tue Oct 20
5:19 pm

Part of Plenary Abstract Session I

A whole-genome immunogenomics framework for African populations: Antigen processing, presentation, and clinically actionable diversity across the HLA, ERAP, TAP, and KIR loci

Room 517/Level 5

Collaborators: Meru University of Science and Technology

Immune systemComputational toolsEpidemiologyGenetic epidemiology

Instantly find 20 buyers from Yemaachi Biotech

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction